Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
1.12
Dollar change
-0.01
Percentage change
-0.88
%
Index- P/E- EPS (ttm)-1.60 Insider Own15.76% Shs Outstand14.20M Perf Week0.98%
Market Cap15.93M Forward P/E- EPS next Y-0.37 Insider Trans0.00% Shs Float11.98M Perf Month18.14%
Income-19.31M PEG- EPS next Q-0.10 Inst Own2.96% Short Float0.84% Perf Quarter60.00%
Sales0.00M P/S- EPS this Y-265.70% Inst Trans-0.73% Short Ratio1.01 Perf Half Y108.96%
Book/sh0.94 P/B1.19 EPS next Y1.77% ROA-72.85% Short Interest0.10M Perf Year-17.65%
Cash/sh1.12 P/C1.00 EPS next 5Y- ROE-93.56% 52W Range0.42 - 1.39 Perf YTD119.61%
Dividend Est.- P/FCF- EPS past 5Y-13.49% ROI-141.89% 52W High-19.55% Beta0.51
Dividend TTM- Quick Ratio3.83 Sales past 5Y0.00% Gross Margin- 52W Low166.67% ATR (14)0.10
Dividend Ex-Date- Current Ratio3.83 EPS Y/Y TTM41.38% Oper. Margin0.00% RSI (14)57.08 Volatility6.87% 8.65%
Employees20 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.67
Option/ShortNo / Yes LT Debt/Eq0.02 EPS Q/Q64.93% Payout- Rel Volume0.39 Prev Close1.13
Sales Surprise- EPS Surprise-40.00% Sales Q/Q- EarningsMay 09 BMO Avg Volume99.26K Price1.12
SMA209.20% SMA5013.47% SMA20050.36% Trades Volume39,169 Change-0.88%
Date Action Analyst Rating Change Price Target Change
May-13-24Initiated Maxim Group Buy $4
May-06-24Upgrade Oppenheimer Perform → Outperform $6
Dec-19-23Resumed ROTH MKM Buy $7
Jun-27-24 12:00PM
Jun-18-24 07:00AM
Jun-06-24 07:00AM
May-17-24 07:00AM
May-10-24 09:55AM
11:57AM Loading…
May-09-24 11:57AM
07:00AM
May-08-24 07:00AM
May-02-24 07:00AM
Apr-24-24 07:00AM
Apr-18-24 07:00AM
Apr-02-24 07:00AM
Mar-25-24 07:06AM
Mar-07-24 12:53PM
07:00AM
07:00AM Loading…
Mar-05-24 07:00AM
Feb-20-24 07:00AM
Feb-14-24 07:00AM
Feb-05-24 07:00AM
Jan-30-24 07:00AM
Jan-03-24 07:00AM
Nov-16-23 07:00AM
Nov-15-23 07:00AM
Nov-13-23 08:00AM
Nov-09-23 08:00AM
Nov-06-23 04:15PM
Oct-30-23 07:00AM
Oct-26-23 07:00AM
Sep-28-23 07:00AM
Aug-29-23 07:00AM
08:00AM Loading…
Aug-14-23 08:00AM
Jun-28-23 07:00AM
Jun-26-23 07:00AM
Jun-21-23 07:00AM
Jun-05-23 07:00AM
Jun-02-23 09:00AM
May-24-23 07:00AM
May-11-23 06:00AM
Apr-26-23 07:00AM
Apr-19-23 07:00AM
Apr-12-23 07:00AM
Mar-29-23 08:30AM
Mar-17-23 07:00AM
Mar-06-23 07:00AM
Feb-21-23 07:00AM
Jan-03-23 07:00AM
Dec-21-22 07:00AM
Nov-30-22 07:00AM
Nov-11-22 06:00AM
Nov-09-22 08:00AM
Nov-01-22 07:00AM
Oct-28-22 07:00AM
Aug-12-22 06:00AM
06:00AM
Aug-01-22 07:00AM
Jun-27-22 08:00AM
Jun-21-22 07:00AM
Jun-09-22 09:00AM
Jun-02-22 07:00AM
May-18-22 07:00AM
May-12-22 06:00AM
May-04-22 07:00AM
Mar-23-22 07:00AM
Mar-14-22 08:00AM
Mar-09-22 06:00AM
Mar-02-22 08:00AM
Feb-10-22 08:00AM
Jan-04-22 07:00AM
Dec-20-21 08:00AM
Dec-16-21 04:05PM
Dec-03-21 08:00AM
Dec-02-21 07:00AM
Nov-23-21 05:34AM
Nov-12-21 07:00AM
Nov-10-21 07:00AM
Nov-09-21 07:00AM
Nov-08-21 07:00AM
Oct-26-21 08:53AM
Oct-15-21 11:42AM
Sep-27-21 07:00AM
Sep-02-21 07:00AM
Sep-01-21 07:18AM
Aug-13-21 08:00AM
Jun-23-21 08:30AM
08:30AM
Jun-17-21 02:44AM
Jun-10-21 07:00AM
May-17-21 08:30PM
May-13-21 09:25AM
May-12-21 07:00AM
Apr-26-21 06:30AM
Mar-29-21 09:00AM
Mar-22-21 07:00AM
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.